Vicore Pharma Holding stock
VICO.STSTOVicore Pharma Holding AB (publ), HealthcareISIN SE0007577895
38Score 38 out of 100, Weak
Price and trend
62 / 100
Price history
+7.6% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 3.4% above it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 69).
The price is 30% below its 52-week high. Largest decline in 11 years: 83% (December 2020 to April 2025).
Chart figures for advanced users
- SMA 50$0.98
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$1.07
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)69
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$0.88
- The lowest closing price of the last twelve months.
- Resistance$1.58
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Vicore Pharma Holding AB (publ) belongs to the Biotechnology industry (Sweden) and, with a market value of $311.37M, is number 288 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $384.33K (down 96.5% year on year) and a loss of $48.08M.
- MEQIRI Score 38 out of 100 (Weak): rank 585 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $77.73M, financial debt $0.Stability 58
Weaknesses
- DilutionShare count up 342% since 2020.Capital allocation 18
- Loss-makingLoss of $51.64M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$33.89M over the last 12 months.Fundamentals 17
The score is held back by fundamentals and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 40 to 38.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Revenue has declined since 2024 (-97% per year), so it is worth watching closely. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −11906%, net −12509%. Last 12 months: net −100%. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterNo financial debt is reported on the balance sheet.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 5 Nov 2026EPS reported −$0.04 (expected −$0.05)above expectations
Analyst estimates
Earnings estimates have barely changed since 10 Nov 2026.
- Earnings per share
- −$0.190.0%
- Revenue
- $313.38K0.0%
- Earnings per share
- −$0.160.0%
- Revenue
- $2.73M0.0%
MEQIRI has stored the estimates since 10 Nov 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Vicore Pharma Holding
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 38
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Autolus TherapeuticsAUTL $330.04M31
- OcugenOCGN $325.87M36
- Turn TherapeuticsTTRX $320.99M45
- MapLight TherapeuticsMPLT $318.78M33
- Kyverna TherapeuticsKYTX $316.64M28
- EvommuneEVMN $312.84M33
- Cabaletta BioCABA $312.79M28
- Allogene TherapeuticsALLO $311.85M27
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = SEK 9.9317)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Dec 2016)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.